tradingkey.logo

SI-BONE Inc

SIBN
查看詳細走勢圖
20.360USD
0.000
收盤 12/26, 16:00美東報價延遲15分鐘
881.05M總市值
虧損本益比TTM

SI-BONE Inc

20.360
0.000
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

0.00%

5天

-0.10%

1月

+4.52%

6月

+10.47%

今年開始到現在

+45.22%

1年

+48.40%

查看詳細走勢圖

TradingKey SI-BONE Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

SI-BONE Inc當前公司基本面數據相對非常健康,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名41/207位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價25.22。中期看,股價處於上升通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

SI-BONE Inc評分

相關信息

行業排名
41 / 207
全市場排名
132 / 4563
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 9 分析師
買入
評級
25.222
目標均價
+32.75%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

SI-BONE Inc亮點

亮點風險
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
業績高增長
公司營業收入穩步增長,連續3年增長57.11%
估值低估
公司最新PE估值-39.94,處於3年歷史低位
機構減倉
最新機構持股41.74M股,環比減少8.47%
PRFDX持倉
明星投資者PRFDX持倉,最新持倉3.74K股

SI-BONE Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

SI-BONE Inc簡介

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
公司代碼SIBN
公司SI-BONE Inc
CEOFrancis (Laura A)
網址https://si-bone.com/

常見問題

SI-BONE Inc(SIBN)的當前股價是多少?

SI-BONE Inc(SIBN)的當前股價是 20.360。

SI-BONE Inc 的股票代碼是什麼?

SI-BONE Inc的股票代碼是SIBN。

SI-BONE Inc股票的52週最高點是多少?

SI-BONE Inc股票的52週最高點是21.070。

SI-BONE Inc股票的52週最低點是多少?

SI-BONE Inc股票的52週最低點是12.495。

SI-BONE Inc的市值是多少?

SI-BONE Inc的市值是881.05M。

SI-BONE Inc的淨利潤是多少?

SI-BONE Inc的淨利潤為-30.91M。

現在SI-BONE Inc(SIBN)的股票是買入、持有還是賣出?

根據分析師評級,SI-BONE Inc(SIBN)的總體評級為買入,目標價格為25.222。

SI-BONE Inc(SIBN)股票的每股收益(EPS TTM)是多少

SI-BONE Inc(SIBN)股票的每股收益(EPS TTM)是-0.510。
KeyAI